Aerovate Therapeutics

Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate’s lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).

Headquarters Boston, MA
Website www.aerovatetx.com
Pipeline status Clinical